Results 21 to 30 of about 3,567,945 (293)

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy

open access: yesClinical Ophthalmology, 2023
Tomoko Miyakubo, Ryo Mukai, Hidetaka Matsumoto, Masahiro Morimoto, Maki Takahashi, Kazuki Nagai, Kosuke Nakamura, Junki Hoshino, Hideo Akiyama Department of Ophthalmology, Gunma University, Graduate School of Medicine, Maebashi, Gunma ...
Miyakubo T   +8 more
doaj  

Five-year outcome of aflibercept intravitreal injection in naïve patients with neovascular age-related macular degeneration using a modified treat-and-extend regimen: Results from a prospective observational study

open access: yesTaiwan Journal of Ophthalmology, 2023
PURPOSE: The purpose is to study the 5-year results of aflibercept monotherapy using an individualized regimen in naïve patients with neovascular AMD (nAMD). MATERIALS AND METHODS: This is a prospective observational study including naïve nAMD patients
Jarret Charles, TRAN Thi Ha Chau
doaj   +1 more source

Hydrodynamic equations for an electron gas in graphene [PDF]

open access: yes, 2016
In this paper we review, and extend to the non-isothermal case, some results concerning the application of the maximum entropy closure technique to the derivation of hydrodynamic equations for particles with spin-orbit interaction and Fermi-Dirac ...
Barletti, Luigi
core   +3 more sources

Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan

open access: yesBMC Ophthalmology, 2022
The management of neovascular age-related macular degeneration (nAMD) has taken a major stride forward with the advent of anti-VEGF agents. The treat-and-extend (T&E) approach is a refined management strategy, tailoring to the individual patient’s ...
Cheng-Kuo Cheng   +15 more
doaj   +1 more source

Real-Life Evidence for Using a Treat-and-Extend Injection Regime for Patients with Central Retinal Vein Occlusion

open access: yesOphthalmology and Therapy, 2019
Introduction To report the 52-week treatment outcomes with intravitreal injections of aflibercept using a treat-and-extend regimen for treating macular edema secondary to central retinal vein occlusion (CRVO). Methods A retrospective analysis of patients
Maria Eleftheriadou   +3 more
doaj   +1 more source

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study

open access: yesBMC Ophthalmology, 2021
Purpose To describe real-life data from wet age-related macular degeneration (AMD) patients treated with anti-vascular endothelial growth factors (VEGFs) and to compare our results with previous studies and clinical trials.
Paolo Corazza   +6 more
doaj   +1 more source

Extended spectrum and extended eigenspaces of quasi-normal operators [PDF]

open access: yesBanach J. Math. Anal. 11, no. 2 (2017), 266-281, 2015
We say that a complex number $\lambda$ is an extended eigenvalueof a bounded linear operator T on a Hilbert space H if there exists anonzero bounded linear operator X acting on H, called extended eigen-vector associated to $\lambda$, and satisfying the equation T X = $\lambda$XT .
arxiv   +1 more source

Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration

open access: yesРоссийский офтальмологический журнал, 2020
Purpose. To evaluate the economic and clinical results of the aflibercept and ranibizumab angiogenesis inhibitors in the treat-and-extend regimen in patients with the “wet” form of age-related macular degeneration (wAMD). Materials and methods.
S. V. Nedogoda   +5 more
doaj   +1 more source

Adenine base editing to treat progeria syndrome and extend the lifespan

open access: yesThe Journal of Cardiovascular Aging, 2021
Hutchinson-Gilford progeria syndrome (HGPS) is an exceedingly rare and hitherto incurable and fatal disease marked by accelerated aging simultaneously affecting a number of organs. Most cases of HGPS are caused by a single copy of a specific single-nucleotide mutation, c.C1824T, in the LMNA (lamin A) gene.
openaire   +4 more sources

Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema [PDF]

open access: yesScientific Reports, 2020
AbstractThis study was performed to investigate the efficacy of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema (DME). This prospective, multicentre, interventional, single-arm, 104-week clinical trial included 48 patients with DME visual impairment.
In Young Chung   +8 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy